The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia

Abstract

Evaluation of: Byrd JC, Furman RR, Coutre SE et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369(1), 32–42 (2013).

Drugs that selectively inhibit Bruton’s tyrosine kinase (BTK), such as the new orally administered agent ibrutinib, are currently under investigation for the treatment of several types of B-cell malignancies. In this article, the authors present results of a Phase Ib/II study of ibrutinib in 85 patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The enthusiasm generated by this paper relies on the fact that ibrutinib given orally on a daily basis produces very high response rates that are durable with minimal side effects. Interestingly, the favorable therapeutic index of ibrutinib may facilitate its use in combination with other agents active in the treatment of CLL. In addition, the use of an effective oral agent like ibrutinib whose efficacy does not translate into a high burden of toxicity should be considered in choosing therapy in the elderly. A challenging issue with ibrutinib is the possibility of overcoming chemotherapy in the treatment of CLL.

Keywords::

• BTK inhibitors
• chronic lymphocytic leukemia treatment
• ibrutinib

Financial & competing interests disclosure

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.

No writing assistance was utilized in the production of this manuscript.

Key issues

• • Ibrutinib, a selective and potent inhibitor of Bruton’s tyrosine kinase (BTK), results in a high rate of durable remissions in a majority of patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

• • The safety profile results reveal a relatively low incidence of serious adverse events.

• • There was no significant difference in the overall response rate (ORR) of patients with either advanced disease or those who exhibited the 17p deletion.

• • Additional answers on the role of ibrutinib will be provided by ongoing Phase III randomized clinical trials comparing ibrutinib with other therapeutic agents in patients with CLL.